Solving the Last Mile Problem -- From FDA Approval to Real-World Adoption
Your patient access programs handle insurance, copay, and navigators. But the real barrier to adoption is practice-level operational readiness. MemberCare solves that.
The Adoption Problem Is Not What You Think
1 to 2 million Americans are eligible for anti-amyloid therapy. Fewer than 20,000 are on treatment. The barrier is not clinical skepticism, not insurance access, not patient awareness. It is practice-level operational readiness.
50+ Discrete Steps
Anti-amyloid therapy requires genetic testing, baseline MRIs, infusion scheduling, ARIA surveillance MRIs at specific intervals, dose calculations, and coordination across 8+ external parties -- per patient, over 24 months.
Managed by Spreadsheets
The reality today: practices use spreadsheets, sticky notes, and manual follow-ups. Nurses spend 6+ hours per day on coordination. It is unsustainable at scale.
Practices Simply Don't Prescribe
Community practices that cannot efficiently manage these protocols choose not to offer the therapy at all. Every practice that cannot prescribe is a practice that does not prescribe.
We Don't Compete With Your Programs -- We Complete Them
Patient access programs (insurance verification, copay assistance, patient navigators) solve the access problem. MemberCare solves the operations problem. Both are required for real-world adoption.
| Layer | Patient Access Programs | MemberCare |
|---|---|---|
| Insurance | Verification, prior auth support, copay cards | AI-generated PA letters with drug-specific justification |
| Patient support | Navigators, call center, patient education | 24/7 AI agents for drug-specific symptom triage |
| Clinical operations | Not addressed | MRI scheduling enforcement, ARIA monitoring, dose calculations, staff coordination |
| Protocol management | Not addressed | 50+ step workflow with automated prerequisite checking and safety blocking rules |
| Between-visit care | Not addressed | RPM, connected devices, patient portal, AI-powered symptom management |
| Real-world evidence | Limited | Structured RWE capture from every patient interaction |
Partnership Models Designed for Pharma
More practices prescribing = more prescriptions = more revenue. Every model accelerates real-world adoption.
Practice Enablement
Pharma funds MemberCare deployment at prescribing sites. Reduce operational barriers at the point of care. Similar in structure to existing hub service programs.
Real-World Evidence
Structured RWE capture from every patient interaction. Treatment outcomes, adverse events, adherence patterns -- data you need for label expansions and payer negotiations.
Co-Development
Pharma and MemberCare co-create AI agents and clinical protocols for new drug launches. AI-powered protocol support ready on launch day -- not 12 months later.
Digital Companion
Branded patient-facing AI agent that supports patients on your specific therapy. Education, side effect management, adherence support, and 24/7 symptom guidance.
What MemberCare Delivers for Your Drug
Pre-built protocol management for complex therapies. MemberCare already has AI agents and clinical protocols for anti-amyloid therapies, oncology regimens, and more.
Protocol Enforcement
Automated workflow with blocking rules: no infusion without prior MRI clearance. ARIA monitoring at required intervals. Dose calculations and titration management.
Drug-Specific AI Agents
Pre-built agents for Kisunla, Leqembi, and 50+ other therapies. Each agent is trained on monitoring schedules, side effects, dosing, and patient education.
Prior Auth Automation
AI-generated PA letters with drug-specific clinical justification. Automated payer rule matching and denial appeal support reduce time-to-treatment.
24/7 Patient Support
Patient-facing AI agents answer drug-specific questions around the clock. Side effects, what to watch for, when to call -- in warm, nurse-like language.
RWE Data Capture
Every patient interaction generates structured data. Treatment outcomes, adverse events, adherence patterns, and protocol compliance -- captured systematically, not anecdotally.
100+ Language Support
AI semantic translation supports global expansion. Patient-facing agents and clinical content available in any language -- aligned with your international launch strategy.
The Math Is Simple
The First Drug to Make Adoption Easy Wins the Installed Base
When multiple therapies compete for the same patient population, the drug whose manufacturer invests in practice enablement captures the prescribing relationship first. Once a practice is operationally set up for one anti-amyloid therapy, switching protocols carries real clinical risk. Investment in adoption infrastructure is investment in market position.
Start With a Pilot
10 practices. 90 days. Drug-specific configuration. Measure the impact on prescribing volume, protocol compliance, and patient outcomes before scaling.
Week 1-2: Configuration
Drug-specific protocol setup. AI agent and clinical protocol deployment. Practice site configuration and staff training.
Week 3-10: Live Operations
Practices enroll and manage patients on the platform. Protocol compliance monitored. RWE data collection begins. Real-time support from MemberCare team.
Week 11-13: Results
Impact analysis on prescribing volume, protocol compliance, patient engagement, and staff productivity. Data-driven decision on scale-up.
Discuss a Pharma Partnership
See how MemberCare can accelerate real-world adoption of your therapy by solving the operational barriers that patient access programs cannot.
Or call us: 214.226.5319